Bronchiolitis Acute ViralNCT05132322

Eliminating Monitor Overuse Trial (EMO Trial)

A study testing Educational Outreach, Audit & Feedback (unit level) and Audit & Feedback (real time, individual-level) in people with Bronchiolitis Acute Viral, run by Children's Hospital of Philadelphia at 51 sites in 2 countries.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record

Search all trials

Trial summary

The purpose of this study is to identify the optimal deimplementation strategies for an overused practice: continuous pulse oximetry monitoring of children hospitalized with bronchiolitis who are not receiving supplemental oxygen. Read more about this study

Who is it for?: Ages 2 months and older
Conditions the study is for: Bronchiolitis Acute Viral
What is being tested?: Educational Outreach, Audit & Feedback (unit level) and Audit & Feedback (real time, individual-level)
Type of treatment: Lifestyle or therapy programme
Could I receive a placebo?: No, everyone receives an active treatment
How many people: 9,265 participants
Where: 51 sitesin 2 countries
Study dates: 1 Dec 2021to Aug 2026
Phase: Interventional
Are there results?: Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 2 months and older
All sexes
No healthy volunteers
Child, Adult, Older adult

Who may be able to join

Infants and children 2 months through 23 months old
Hospitalized on non-ICU wards participating in the trial
Cared for by generalist inpatient services (e.g. general pediatrics, hospital medicine)
Primary diagnosis of bronchiolitis in most recent physician progress note
Not actively receiving supplemental oxygen ("in room air")
Last documented receipt of supplemental oxygen >1 hour prior to direct observational data collection

Show all 11Show fewer

Infants and children 2 months through 23 months old
Hospitalized on non-ICU wards participating in the trial
Cared for by generalist inpatient services (e.g. general pediatrics, hospital medicine)
Primary diagnosis of bronchiolitis in most recent physician progress note
Actively receiving ≥2 Liters/minute (2L/min) supplemental oxygen or 21% room air flow

Who cannot join

Documented apnea or cyanosis during the current illness
Extreme prematurity (<28 weeks completed gestation)
Cardiac disease
Pulmonary hypertension
Chronic lung disease
Home oxygen requirement

Show all 20Show fewer

Neuromuscular disease
Immunodeficiency
Cancer
Severe Acute Respiratory Syndrome Coronavirus 2 (Covid-19 / SARS-CoV-2)-related illness (known or suspected, including multisystem inflammatory syndrome in children multi-system inflammatory syndrome in children (MIS-C)
Population b: Bronchiolitis patients directly observed while receiving supplemental oxygen (for underuse evaluation).
Extreme prematurity (<28 weeks completed gestation)
Cardiac disease
Pulmonary hypertension
Chronic lung disease
Home oxygen requirement
Neuromuscular disease
Immunodeficiency
Cancer
Severe Acute Respiratory Syndrome Coronavirus 2 [Covid-19 / SARS-CoV-2 (known or suspected)]

Trial locations and contacts

51 sites in 2 countries.

Country

City, postcode or hospital

51 sites in 2 countries

United States50 sites

Akron Children's Hospital
Akron, Ohio, 44308
Albany Medical Center
Albany, New York, 12208
CS Mott Children's Hospital
Ann Arbor, Michigan, 48108
Children's Hospital Colorado
Aurora, Colorado, 80045
Children's of Alabama
Birmingham, Alabama, 35233
Boston Children's Hospital
Boston, Massachusetts, 02115
University of Vermont Children's Hospital
Burlington, Vermont, 05401
Ann & Robert H. Lurie Children's Hospital of Chicago
Chicago, Illinois, 60611
Northwestern University
Chicago, Illinois, 60611
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, 45229
Nationwide Children's Hospital
Columbus, Ohio, 43205
Children's Medical Center Dallas
Dallas, Texas, 75235
University of California Davis
Davis, California, 95616
Rady Children's Hospital/UCSD
Encinitas, California, 92024
Inova Children's Hospital
Falls Church, Virginia, 22042
Children's Memorial Hermann
Houston, Texas, 77030
Texas Children's Hospital
Houston, Texas, 77030
Texas Children's Hospital West Campus
Houston, Texas, 77094
Hoops Family Children's Hospital at Marshall University
Huntington, West Virginia, 25701
Riley Hospital for Children at IU Health
Indianapolis, Indiana, 46202
Children's Mercy Kansas City
Kansas City, Missouri, 64108
CHOP King of Prussia Hospital
King of Prussia, Pennsylvania, 19406
Children's Hospital at Dartmouth-Hitchcock
Lebanon, New Hampshire, 03756
Children's Hospital Los Angeles
Los Angeles, California, 90027
Valley Children's Hospital
Madera, California, 93636
Children's Wisconsin
Milwaukee, Wisconsin, 53226
Children's Minnesota
Minneapolis, Minnesota, 55404
Monroe Carell Jr. Children's Hospital at Vanderbilt
Nashville, Tennessee, 37232
Yale-New Haven Children's Hospital
New Haven, Connecticut, 06510
Cohen Children's Medical Center
New Hyde Park, New York, 11040
NYP-Morgan Stanley Children's Hospital
New York, New York, 10032
Komansky Children's Hospital/New York Presbyterian Medical Center /Weill Cornell Medicine
New York, New York, 10065
Children's Hospital of The King's Daughters
Norfolk, Virginia, 23507
Children's Hospital at Oklahoma University Medical Center
Oklahoma City, Oklahoma, 73104
Children's Hospital Orange County
Orange, California, 92868
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, 19104
University of Pennsylvania
Philadelphia, Pennsylvania, 19104
Children's Hospital of Pittsburgh of UPMC
Pittsburgh, Pennsylvania, 15224
CHOP Pediatric Care at Penn Medicine/Princeton Health
Princeton, New Jersey, 08536
Children's Hospital of Richmond at VCU
Richmond, Virginia, 23298
University of Rochester Golisano Children's Hospital
Rochester, New York, 14642
Primary Children's Hospital
Salt Lake City, Utah, 84113
Seattle Children's Hospital
Seattle, Washington, 98105
CHOP Grand View Hospital
Sellersville, Pennsylvania, 18960
Lucile Packard Children's Hospital Stanford
Stanford, California, 94304
Upstate Golisano Children's Hospital
Syracuse, New York, 13210
Children's Hospital at Montefiore
The Bronx, New York, 10467
Texas Children's Hospital The Woodlands
The Woodlands, Texas, 77384
CHOP Care Network at Virtua
Voorhees Township, New Jersey, 08043
Children's National Medical Center
Washington D.C., District of Columbia, 20010

Other trials in United States

Canada1 site

Alberta Children's Hospital
Calgary, AB T3B 6A8

Other trials in Canada

About this study

Official title: Eliminating Monitor Overuse (EMO) Hybrid Effectiveness-Deimplementation Trial

Conditions: Bronchiolitis Acute Viral
Being tested: Educational Outreach, Audit & Feedback (unit level), Audit & Feedback (real time, individual-level), Clinical Pathway Integrated into Electronic Health Record
Keywords: pulse oximetry, deimplementation, cluster-randomized trial, effectiveness-implementation hybrid trial, implementation science

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Educational OutreachBehavioural
Educational outreach includes staff-targeted educational materials and outreach sessions summarizing the current evidence and guideline recommendations for pulse oximetry use in bronchiolitis.
Audit & Feedback (unit level)Behavioural
Weekly unit-level feedback of each hospital's guideline-concordant practice will be distributed to sites in the form of a visual dashboard that includes comparisons over time and between hospitals. The dashboard will then be shared locally on a weekly basis with clinicians in person and electronically.
Audit & Feedback (real time, individual-level)Behavioural
Real-time feedback will occur at the individual clinician level. When collecting data on an individual patient, data collectors encountering guideline-discordant continuous monitoring are empowered to briefly ask any available clinician responsible for that patient's care, in a nonjudgmental way, about indications for monitoring that patient. The clinician is ultimately responsible for deciding if any changes are indicated.
Clinical Pathway Integrated into Electronic Health RecordBehavioural
Clinical pathways guide clinicians step-by-step through evidence-based care. Based on the existing guidelines for physiologic monitoring in bronchiolitis, the pathway will clearly specify (a) situations when it is appropriate to initiate intermittent SpO2 measurement instead of continuous SpO2 monitoring, and (b) when it is appropriate to discontinue continuous SpO2 monitoring altogether, and transition to intermittent SpO2 measurement. In order to be visible to clinicians as they perform patient care, the pathway will be integrated into the electronic health record at sites randomized to this intervention.

Study groups in NCT05132322
Study group	Role	What they receive
Unlearning Only	Active comparator	Includes educational outreach and audit \& feedback. Receives: Behavioral: Educational Outreach; Behavioral: Audit & Feedback (unit level); Behavioral: Audit & Feedback (real time, individual-level)
Unlearning + Substitution	Experimental	Includes educational outreach, audit \& feedback, and an electronic health record-integrated clinical pathway to support appropriate use of pulse oximetry. Receives: Behavioral: Educational Outreach; Behavioral: Audit & Feedback (unit level); Behavioral: Audit & Feedback (real time, individual-level); Behavioral: Clinical Pathway Integrated into Electronic Health Record

What is being measured

The primary outcome is the main question the study is designed to answer.

Deimplementation Sustainment
The primary outcome specified in the protocol is deimplementation sustainment, a "difference in differences" outcome based on statistical comparisons based on pulse oximetry overuse across trial phases and arms. Pulse oximetry overuse is operationally defined as percent of patient observations monitored using continuous pulse oximetry while not receiving supplemental oxygen (measured using direct observation).
The least metabolized form of the data for pulse oximetry overuse, raw proportions across trial phases and arms, is reported here. Results of the specific analysis used to report the trial's pre-specified primary outcome of deimplementation sustainment is reported in Statistical Analysis 1.
Measured: Data from the baseline phase (approximately 7 months) was compared to data from the sustainment phase (approximately 4 months). Only data from baseline and sustainment phases are used in this calculation.

Secondary outcomes (5)

Count of Observations During Which the Patient Was Not Receiving Supplemental Oxygen and Yet Was Continuously Monitored Using Pulse Oximetry During the Baseline Phase of the Trial
This measure is assessed as the count of patient observations monitored using continuous pulse oximetry while not receiving supplemental oxygen (measured using direct observation) in the baseline phase.
In order to assist in interpretation, this can also be viewed below as a proportion or a percent of the total number of observations. The denominator is the count of observations of patients not receiving supplemental oxygen. The numerator is the count of observations of patients not receiving supplemental oxygen who are also monitored using continuous pulse oximetry. The numerator count is divided by the denominator count to calculate a proportion. The proportion is multiplied by 100 to obtain a percent. This is expressed below as a count with the percentage automatically calculated by the clinicaltrials.gov system.
Measured: This measure used data from the baseline phase (approximately 7 months).
Count of Observations During Which the Patient Was Not Receiving Supplemental Oxygen and Yet Was Continuously Monitored Using Pulse Oximetry During the Active Deimplementation Phase of the Trial
This measure is assessed as the count of patient observations monitored using continuous pulse oximetry while not receiving supplemental oxygen (measured using direct observation) in the active deimplementation phase.
In order to assist in interpretation, this can also be viewed below as a proportion or a percent of the total number of observations. The denominator is the count of observations of patients not receiving supplemental oxygen. The numerator is the count of observations of patients not receiving supplemental oxygen who are also monitored using continuous pulse oximetry. The numerator count is divided by the denominator count to calculate a proportion. The proportion is multiplied by 100 to obtain a percent. This is expressed below as a count with the percentage automatically calculated by the clinicaltrials.gov system.
Measured: Data from the active deimplementation phase (approximately 5 months).
Count of Observations During Which the Patient Was Not Receiving Supplemental Oxygen and Yet Was Continuously Monitored Using Pulse Oximetry During the Sustainment Phase of the Trial
This measure is assessed as the count of patient observations monitored using continuous pulse oximetry while not receiving supplemental oxygen (measured using direct observation) in the sustainment phase.
In order to assist in interpretation, this can also be viewed below as a proportion or a percent of the total number of observations. The denominator is the count of observations of patients not receiving supplemental oxygen. The numerator is the count of observations of patients not receiving supplemental oxygen who are also monitored using continuous pulse oximetry. The numerator count is divided by the denominator count to calculate a proportion. The proportion is multiplied by 100 to obtain a percent. This is expressed below as a count with the percentage automatically calculated by the clinicaltrials.gov system.
Measured: Data from the sustainment phase (approximately 4 months).
Duration of Oxygen Supplementation
The oxygen supplementation duration is the total duration of time during which a patient is documented as receiving supplemental oxygen during hospitalization.
Measured: Up to 4 years
Length of Hospital Stay
The length of hospital stay is the duration of time that elapses between the time a patient is admitted with bronchiolitis to an inpatient unit of the hospital until the time they are discharged from the hospital, using data manually abstracted from the electronic health record chart.
Measured: Up to 4 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

1 Dec 2021Aug 2026

First posted24 Nov 2021
Study start1 Dec 2021
Primary completion31 Mar 2024
Study completionAug 2026 (estimated)

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
Publications (3)Papers the sponsor has linked to this study.
Other trials for Bronchiolitis Acute ViralStudies of the same condition, open and under way.
More trials run by Children's Hospital of PhiladelphiaThe sponsor's other registered studies.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Interventional
Phase: Phase N/A
Primary purpose: Health services research
Allocation: Randomised
Intervention model: Parallel groups
Masking: None (open label)
Enrolment: 9,265 participants (actual)

IDs, dates and publications

ClinicalTrials.gov ID: NCT05132322
Sponsor's protocol ID: 21-018560
Other IDs: U01HL159880
Status last verified: Feb 2026
First submitted: 10 Nov 2021
Last updated: 13 Feb 2026
Results posted: Yes, on ClinicalTrials.gov
Data monitoring committee: Yes
FDA-regulated drug: No
FDA-regulated device: No
Individual data sharing: Yes: Final Research Data (the dataset necessary to document and support the primary research findings).

Publications

Xiao R, Bonafide CP, Williams NJ, Cidav Z, Landrigan CP, Faerber J, Makeneni S, Wolk CB, Schondelmeyer AC, Brady PW, Beidas RS, Schisterman EF. Eliminating Monitor Overuse (EMO) type III effectiveness-deimplementation cluster-randomized trial: Statistical analysis plan. Contemp Clin Trials Commun. 2023 Oct 2;36:101219. doi: 10.1016/j.conctc.2023.101219. eCollection 2023 Dec.
PubMed 37842322
Faerber JA, Xiao R, Makeneni S, Schisterman EF, Brady PW, Schondelmeyer AC, Landrigan CP, Lucey K, Lee V, Gregory PF, Prasto J, Parthasarathy P, Greenfield M, Solomon C, Brent CR, Albanowski K, Beidas RS, Bonafide CP; Pediatric Research in Inpatient Settings (PRIS) Network. Sustainment of continuous pulse oximetry deimplementation: Analysis of Eliminating Monitor Overuse study data from six hospitals. J Hosp Med. 2023 Aug;18(8):724-729. doi: 10.1002/jhm.13154. Epub 2023 Jun 28.
PubMed 37380625
Bonafide CP, Xiao R, Schondelmeyer AC, Pettit AR, Brady PW, Landrigan CP, Wolk CB, Cidav Z, Ruppel H, Muthu N, Williams NJ, Schisterman E, Brent CR, Albanowski K, Beidas RS; Pediatric Research in Inpatient Settings (PRIS) Network. Sustainable deimplementation of continuous pulse oximetry monitoring in children hospitalized with bronchiolitis: study protocol for the Eliminating Monitor Overuse (EMO) type III effectiveness-deimplementation cluster-randomized trial. Implement Sci. 2022 Oct 21;17(1):72. doi: 10.1186/s13012-022-01246-z.
PubMed 36271399

Want to know more?

The sponsor has not listed a contact. The official record may have more details.

Talk to your doctor first and take this page with you. Only the study team can confirm whether you can join.

Questions to ask the study team

What is the study trying to find out?
What would I need to do, and how often would I visit?
Could I receive a placebo instead of the treatment?
What are the possible risks and benefits for me?
Will it cost me anything? Are travel or time paid for?
Can I keep seeing my own doctor during the study?
What happens when the study ends?

See locations

Recruiting
Respiratory Physiotherapy and Hospitalization in Infants With Bronchiolitis
Acute Viral Bronchiolitis
Not yet recruitingObservational study
Internal Jugular Vein Respiratory Variability as a Marker of Disease Severity in Infant Bronchiolitis
Acute Bronchiolitis, Viral Bronchiolitis
Active, not recruitingObservational study
Effectiveness of Immunization in Preventing Severe Acute Respiratory Infection RSV in Children Under 6 Months in Bogotá
Respiratory Syncytial Virus Infections, Severe Acute Respiratory Infection
Not yet recruitingObservational study
Risk Factors and Severity of Bronchiolitis in Hospitalized Children at Assiut University Hospital
Bronchiolitis, Acute Bronchiolitis
Not yet recruitingObservational study
Gut Microbiome and Immune Response in Severe RSV Infection in Vietnamese Infants
Respiratory Syncytial Virus Infection, Bronchiolitis

All Bronchiolitis Acute Viral trials

Study at a glance

From the registry record, last updated by the sponsor on 13 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.

Official title: Eliminating Monitor Overuse (EMO) Hybrid Effectiveness-Deimplementation Trial
ClinicalTrials.gov ID: NCT05132322
Acronym / sponsor ID: 21-018560
Conditions: Bronchiolitis Acute Viral
Keywords: pulse oximetry, deimplementation, cluster-randomized trial, effectiveness-implementation hybrid trial, implementation science
Study type: Interventional
Recruitment status: Active, not recruiting
Enrolment: 9,265 participants (actual)
Lead sponsor: Children's Hospital of PhiladelphiaUniversity, hospital or other
Collaborators: National Heart, Lung, and Blood Institute (NHLBI), University of Pennsylvania, Boston Children's Hospital, Children's Hospital Medical Center, Cincinnati, Pediatric Research in Inpatient Settings (PRIS) Network
Study start: 1 Dec 2021 (actual)
Primary completion: 31 Mar 2024 (actual)
Study completion: Aug 2026 (estimated)
First posted: 24 Nov 2021 (actual)
Results: Posted 13 Feb 2026

Clinical summary

The research question as the sponsor registered it. This describes what the study plans to test, not what it found.

Study design

Primary purpose: Health services research
Allocation: Randomised
Intervention model: Parallel groups
Masking: None (open label)
Number of arms: 2

Arm	Type	Receives
Unlearning Only	Active comparator	Behavioral: Educational Outreach, Behavioral: Audit & Feedback (unit level), Behavioral: Audit & Feedback (real time, individual-level)Includes educational outreach and audit \& feedback.
Unlearning + Substitution	Experimental	Behavioral: Educational Outreach, Behavioral: Audit & Feedback (unit level), Behavioral: Audit & Feedback (real time, individual-level), Behavioral: Clinical Pathway Integrated into Electronic Health RecordIncludes educational outreach, audit \& feedback, and an electronic health record-integrated clinical pathway to support appropriate use of pulse oximetry.

Who may qualify

Ages: 2 months and older
Sex: All
Healthy volunteers: Not accepted
Age groups: Child, Adult, Older adult

Key inclusion criteria (11 listed)

Infants and children 2 months through 23 months old
Hospitalized on non-ICU wards participating in the trial
Cared for by generalist inpatient services (e.g. general pediatrics, hospital medicine)
Primary diagnosis of bronchiolitis in most recent physician progress note
Not actively receiving supplemental oxygen ("in room air")

Key exclusion criteria (20 listed)

Documented apnea or cyanosis during the current illness
Extreme prematurity (<28 weeks completed gestation)
Cardiac disease
Pulmonary hypertension
Chronic lung disease

Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.

Interventions

Intervention	Type	Arms
Educational OutreachEducational outreach includes staff-targeted educational materials and outreach sessions summarizing the current evidence and guideline recommendations for pulse oximetry use in bronchiolitis.	Behavioural	Unlearning + Substitution, Unlearning Only
Audit & Feedback (unit level)Weekly unit-level feedback of each hospital's guideline-concordant practice will be distributed to sites in the form of a visual dashboard that includes comparisons over time and between hospitals. The dashboard will then be shared locally on a weekly basis with clinicians in person and electronically.	Behavioural	Unlearning + Substitution, Unlearning Only
Audit & Feedback (real time, individual-level)Real-time feedback will occur at the individual clinician level. When collecting data on an individual patient, data collectors encountering guideline-discordant continuous monitoring are empowered to briefly ask any available clinician responsible for that patient's care, in a nonjudgmental way, about indications for monitoring that patient. The clinician is ultimately responsible for deciding if any changes are indicated.	Behavioural	Unlearning + Substitution, Unlearning Only
Clinical Pathway Integrated into Electronic Health RecordClinical pathways guide clinicians step-by-step through evidence-based care. Based on the existing guidelines for physiologic monitoring in bronchiolitis, the pathway will clearly specify (a) situations when it is appropriate to initiate intermittent SpO2 measurement instead of continuous SpO2 monitoring, and (b) when it is appropriate to discontinue continuous SpO2 monitoring altogether, and transition to intermittent SpO2 measurement. In order to be visible to clinicians as they perform patient care, the pathway will be integrated into the electronic health record at sites randomized to this intervention.	Behavioural	Unlearning + Substitution

Primary outcome

Deimplementation Sustainment
Time frame: Data from the baseline phase (approximately 7 months) was compared to data from the sustainment phase (approximately 4 months). Only data from baseline and sustainment phases are used in this calculation.
The primary outcome specified in the protocol is deimplementation sustainment, a "difference in differences" outcome based on statistical comparisons based on pulse oximetry overuse across trial phases and arms. Pulse oximetry overuse is operationally defined as percent of patient observations monitored using continuous pulse oximetry while not receiving supplemental oxygen (measured using direct observation). The least metabolized form of the data for pulse oximetry overuse, raw proportions across trial phases and arms, is reported here. Results of the specific analysis used to report the trial's pre-specified primary outcome of deimplementation sustainment is reported in Statistical Analysis 1.

5 secondary outcomes

Count of Observations During Which the Patient Was Not Receiving Supplemental Oxygen and Yet Was Continuously Monitored Using Pulse Oximetry During the Baseline Phase of the Trial
Time frame: This measure used data from the baseline phase (approximately 7 months).
Count of Observations During Which the Patient Was Not Receiving Supplemental Oxygen and Yet Was Continuously Monitored Using Pulse Oximetry During the Active Deimplementation Phase of the Trial
Time frame: Data from the active deimplementation phase (approximately 5 months).
Count of Observations During Which the Patient Was Not Receiving Supplemental Oxygen and Yet Was Continuously Monitored Using Pulse Oximetry During the Sustainment Phase of the Trial
Time frame: Data from the sustainment phase (approximately 4 months).
Duration of Oxygen Supplementation
Time frame: Up to 4 years
Length of Hospital Stay
Time frame: Up to 4 years

Results and safety

Results posted to the registry on 13 Feb 2026, as reported by the sponsor. Figures are copied from the record, not re-analysed. Full results on ClinicalTrials.gov.

Participant flow

Group	Started	Completed
Unlearning Only	982	982
Unlearning + Substitution	888	888

Primary outcome: Deimplementation Sustainment

Time frame: Data from the baseline phase (approximately 7 months) was compared to data from the sustainment phase (approximately 4 months). Only data from baseline and sustainment phases are used in this calculation.. Count of units. Unit: pulse oximetry use observations

Measure	Unlearning Only - Baseline Phase n = 982	Unlearning + Substitution - Baseline Phase n = 888	Unlearning Only - Active Deimplementation Phase n = 861	Unlearning + Substitution - Active Deimplementation Phase n = 720	Unlearning Only - Sustainment Phase n = 955	Unlearning + Substitution - Sustainment Phase n = 701
Value	610	564	277	243	376	317

Unlearning Only - Baseline Phase vs Unlearning + Substitution - Baseline Phase vs Unlearning Only - Sustainment Phase vs Unlearning + Substitution - Sustainment Phase: Mean Difference (Net): 3.1 (95% CI -2.7 to 8.8), p = .29, Regression, Logistic

Population analysed: Each hospital has multiple participants. Each participant may have 1 or more observations of pulse oximetry use.

5 secondary outcomes are reported in the full results.

Adverse events

Time frame: Adverse event (AE) data were collected in the active deimplementation phase (approximately 5 months), the sustainment phase (approximately 4 months), and the exploratory phase (approximately 4 months). Within each phase, each participant was assessed during their entire period of hospitalization (with the duration varying by patient depending on their severity of illness) and for the 7 days following hospital discharge.. Other adverse events reported at 0% frequency or more

Group	Serious adverse events	Other adverse events	Deaths
Unlearning Only: Bronchiolitis Patients (for Primary Outcome) in Active Deimplementation Phase	0 of 861 (0%)	6 of 861 (0.7%)	0 of 861
Unlearning + Substitution: Bronchiolitis Patients (for Primary Outcome) in Active Deimplement. Phase	0 of 720 (0%)	6 of 720 (0.8%)	0 of 720
Unlearning Only: Bronchiolitis Patients (for Primary Outcome) in Sustainment Phase	0 of 955 (0%)	2 of 955 (0.2%)	0 of 955
Unlearning + Substitution: Bronchiolitis Patients (for Primary Outcome) in Sustainment Phase	0 of 701 (0%)	10 of 701 (1.4%)	0 of 701
Unlearning Only: Bronchiolitis Patients (for Exploratory Outcomes)	0 of 309 (0%)	3 of 309 (1%)	0 of 309
Unlearning + Substitution: Bronchiolitis Patients (for Exploratory Outcomes)	0 of 345 (0%)	0 of 345 (0%)	0 of 345

Loading the posted results from ClinicalTrials.gov…

Research links

Official record on ClinicalTrials.govLast updated by the sponsor 13 Feb 2026.
Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
Derived from this study: PubMed 37842322Xiao R, Bonafide CP, Williams NJ, Cidav Z, Landrigan CP, Faerber J, Makeneni S, Wolk CB, Schondelmeyer AC, Brady PW, Beidas RS, Schisterman EF. Eliminating Monitor Overuse (EMO) type III effectiveness-deimplementation cluster-randomized trial: Statistical analysis plan. Contemp Clin Trials Commun. 2023 Oct 2;36:101219. doi: 10.1016/j.conctc.2023.101219. eCollection 2023 Dec.
Derived from this study: PubMed 37380625Faerber JA, Xiao R, Makeneni S, Schisterman EF, Brady PW, Schondelmeyer AC, Landrigan CP, Lucey K, Lee V, Gregory PF, Prasto J, Parthasarathy P, Greenfield M, Solomon C, Brent CR, Albanowski K, Beidas RS, Bonafide CP; Pediatric Research in Inpatient Settings (PRIS) Network. Sustainment of continuous pulse oximetry deimplementation: Analysis of Eliminating Monitor Overuse study data from six hospitals. J Hosp Med. 2023 Aug;18(8):724-729. doi: 10.1002/jhm.13154. Epub 2023 Jun 28.
Derived from this study: PubMed 36271399Bonafide CP, Xiao R, Schondelmeyer AC, Pettit AR, Brady PW, Landrigan CP, Wolk CB, Cidav Z, Ruppel H, Muthu N, Williams NJ, Schisterman E, Brent CR, Albanowski K, Beidas RS; Pediatric Research in Inpatient Settings (PRIS) Network. Sustainable deimplementation of continuous pulse oximetry monitoring in children hospitalized with bronchiolitis: study protocol for the Eliminating Monitor Overuse (EMO) type III effectiveness-deimplementation cluster-randomized trial. Implement Sci. 2022 Oct 21;17(1):72. doi: 10.1186/s13012-022-01246-z.
Individual participant dataSharing planned: Yes. Final Research Data (the dataset necessary to document and support the primary research findings).

Related trials for Bronchiolitis Acute Viral

Recruiting
Respiratory Physiotherapy and Hospitalization in Infants With Bronchiolitis
Acute Viral Bronchiolitis
Not yet recruitingObservational study
Internal Jugular Vein Respiratory Variability as a Marker of Disease Severity in Infant Bronchiolitis
Acute Bronchiolitis, Viral Bronchiolitis
Active, not recruitingObservational study
Effectiveness of Immunization in Preventing Severe Acute Respiratory Infection RSV in Children Under 6 Months in Bogotá
Respiratory Syncytial Virus Infections, Severe Acute Respiratory Infection
Not yet recruitingObservational study
Risk Factors and Severity of Bronchiolitis in Hospitalized Children at Assiut University Hospital
Bronchiolitis, Acute Bronchiolitis
Not yet recruitingObservational study
Gut Microbiome and Immune Response in Severe RSV Infection in Vietnamese Infants
Respiratory Syncytial Virus Infection, Bronchiolitis

Referral and contact

AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.

Christopher P Bonafide, MD, MSCE principal investigator

Children's Hospital of Philadelphia

Rinad S Beidas, PhD principal investigator

Northwestern University

51 sites in 2 countries: see every site and its status.

Questions about this trial

What is this clinical trial studying?

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 11 inclusion and 20 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: under way, not looking for participants, as of the sponsor's last update on 13 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 51 sites in United States, Canada. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Yes. Results are posted in the registry (first posted 13 Feb 2026). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Deimplementation Sustainment (time frame: Data from the baseline phase (approximately 7 months) was compared to data from the sustainment phase (approximately 4 months). Only data from baseline and sustainment phases are used in this calculation.). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05132322, which also lists 3 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Feb 2026.